We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04508530
Previous Study | Return to List | Next Study

Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04508530
Recruitment Status : Recruiting
First Posted : August 11, 2020
Last Update Posted : May 12, 2023
Information provided by (Responsible Party):

Brief Summary:
A Superiority Study To Compare The Effect of Panzyga Versus Placebo in Patients with Pediatric Acute-onset Neuropsychiatric Syndrome

Condition or disease Intervention/treatment Phase
Pediatric Acute-Onset Neuropsychiatric Syndrome Biological: Panzyga Other: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 92 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Superiority Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome
Actual Study Start Date : June 30, 2021
Estimated Primary Completion Date : October 2024
Estimated Study Completion Date : October 2024

Arm Intervention/treatment
Experimental: Panzyga
Panzyga 10% IVIG
Biological: Panzyga
Panzyga 10% IVIG

Placebo Comparator: Placebo
Other: Placebo

Primary Outcome Measures :
  1. CY-BOCS score - Primary [ Time Frame: 9 weeks ]
    Improvement of neuropsychiatric symptomatology and behavior in PANS patients determined by clinician-rated Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) score. The mean changes in the total CY-BOCS score from Baseline to Week 9 will be compared between Panzyga and placebo treatment to demonstrate superiority. The CY-BOCS scale score is a clinician-rated, semi-structured interview for rating the presence or absence, as well as the severity of obsessive-compulsive symptoms.The CY-BOCS yields a total obsession score, a total compulsion score and combined total score (maximum total CY-BOCS score=40).

Secondary Outcome Measures :
  1. CY-BOCS score - Secondary [ Time Frame: 18 weeks ]
    CY-BOCS score at the end of the follow-up period at Week 18 will be compared to the Week 9 scores within the (Panzyga - Placebo) treatment sequence group

  2. Clinical Global Impression [ Time Frame: 18 weeks ]
    To assess behavioral changes via the Clinical Global Impression (CGI) assessment. The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1 = normal; not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. The Clinical Global Impression - Improvement scale (CGI-I) is a 7-point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention and is rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.

  3. Parent OC Impact Scale [ Time Frame: 18 weeks ]
    To assess behavioral changes via the Parent OC Impact Scale - COIS-RP assessment. The Child Obsessive-Compulsive Impact Scale-Revised consists of parallel 33-item parent and child-report versions assessing impairment due to OCD across multiple functional domains. Items are rated on a 4-point scale from 0 (not at all) to 3 (very much).

  4. Child OC Impact Scale [ Time Frame: 18 weeks ]
    To assess behavioral changes via the Child OC Impact Scale COIS-RC assessment. The Child Obsessive-Compulsive Impact Scale-Revised consists of parallel 33-item parent and child-report versions assessing impairment due to OCD across multiple functional domains. Items are rated on a 4-point scale from 0 (not at all) to 3 (very much).

  5. SNAP-IV 26 item Scale [ Time Frame: 18 weeks ]
    To assess behavioral changes via the Swanson, Nolan, And Pelham Scale - Version IV (SNAP-IV) 26 item Scale. It is a 26-item, parent- or teacher-reported scale which elicits reporting on each of the DSM cardinal symptoms of Attention-Deficit Hyperactivity Disorder (ADHD), Oppositional Defiant Disorder (ODD), and Conduct Disorder (CD) in children and adolescents. The 26-item scale also includes items on aggression, mood, and school performance and behavior. It is used extensively in ADHD and disruptive behavior disorder intervention trials and is sensitive to change

  6. Parent Tic Questionnaire (PTQ) [ Time Frame: 18 weeks ]
    To assess behavioral changes via the Parent Tic Questionnaire (PTQ). The PTQ assesses tic severity in the past week, allowing for individual parent ratings of tic presence or absence.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients ≥6 to ≤17 years of age.
  2. Confirmed diagnosis of moderate to severe PANS with prominent and stable obsessive-compulsive disorder (OCD) symptoms (i.e. Clinical Global Impression (CGI)-Severity-OCD rating of ≥ 4 or higher on 2 ratings without a change of more than 1 unit between measurements) based on the following criteria:

    1. Abrupt dramatic onset of OCD meeting DSM-5 diagnostic criteria for OCD as confirmed by the MINI-KID-7
    2. Concurrent presence of additional neuropsychiatric symptoms, with similarly severe and acute onset, from at least two of the following seven categories, that are not better explained by a known neurologic or medical disorder, such as Sydenham chorea (SC), systemic lupus erythematosus, Tourette disorder, or other:

      • Anxiety (particularly, separation anxiety)
      • Emotional lability (extreme mood swings) and/or depression
      • Irritability, aggression and/or severely oppositional behaviors
      • Behavioral (developmental) regression (examples, talking baby talk,throwing temper tantrums, etc.)
      • Deterioration in school performance
      • Sensory or motor abnormalities
      • Somatic signs and symptoms, including sleep disturbances, bed wetting or urinary frequency
  3. Signed informed consent of patient's legal representative(s)/guardians(s). If patients are old enough to understand the risks and benefits of the study (as determined by each institution), they should provide written assent/consent.
  4. Legal representative(s)/guardians(s) must be capable of understanding and complying with the relevant aspects of the study protocol.

Patients who will additionally meet the following optional inclusion criteria will be identified as patients with Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS):

  1. An episodic (relapsing-remitting) course of symptom severity
  2. Temporal association between symptoms onset or exacerbation and infections with group A streptococcal infection (GAS, positive throat culture and/or anti-GAS antibody titers)

Exclusion Criteria

  1. Onset of initial PANS episode more than seven months prior to first investigational medicinal product (IMP) treatment. In patients with relapsing episodes, initial episode may not have been more than 12 months prior to Screening, must have fully resolved based on investigator's judgment, and the recurrence must be less than six months prior to Screening.
  2. Contraindication to receiving intravenous immunoglobulin (IVIG), including:

    1. History of severe hypersensitivity, e.g. anaphylaxis or severe systemic response, to immunoglobulin, blood or plasma derived products, or any component of Panzyga.
    2. Immunoglobulin (Ig) A deficiency with antibodies to IgA (<7 mg/dL).
    3. Hyperviscosity syndromes or known or suspected hypercoagulable conditions as inferred from clinical history, which can increase risks of thrombosis associated with IVIG administration.
    4. History of arterial or venous thrombotic or thromboembolic events (TEEs) within the last year prior to Baseline. History of acquired or inherited thrombophilia any time prior to Baseline.
    5. Need for live virus vaccine within three months after receiving study drug.
    6. Renal dysfunction (creatinine >120 µmol/L or 1.36 mg/dL), history of renal dysfunction, or known risk factor for renal dysfunction (chronic renal insufficiency, diabetes mellitus, taking known nephrotoxic medication) .
  3. Severely restricted food intake likely to require parenteral nutrition, and <5th percentile BMI-for-age (BMI Percentile Calculator for Child and Teen based on Centers for Disease Control and Prevention growth charts for children and teens ages 2 through 19 years)
  4. Body mass index ≥ 40 kg/m2
  5. Presence of symptoms consistent with autism or schizophrenia, bipolar disorder, or other psychotic disorder (unless psychotic symptoms have onset coincident with PANS).
  6. Presence of serious or unstable medical illness, psychiatric (e.g. high suicide risk) or behavioral symptoms that would make participation unsafe or study procedures too difficult to tolerate.
  7. Treatment with systemic corticosteroids within eight weeks before randomization.
  8. History of rheumatic fever, including SC (neurological manifestation).
  9. Past treatment of neuropsychiatric symptoms with immunomodulatory therapy (such as IVIG, rituximab or mycophenolate mofetil) or plasmapheresis.
  10. Initiation of cognitive behavioral therapy (CBT) within eight weeks before randomization.
  11. Start of treatment or change in dosing with selective serotonin reuptake inhibitors [SSRIs] within eight weeks before randomization.
  12. Treatment with alpha-2 agonists or antipsychotics within eight weeks before randomization.
  13. Start of treatment or change in dosing with stimulants (Methylphenidate, Amphetamine and similar products) for Attention-Deficit Hyperactivity Disorder (ADHD) within four weeks prior to randomization.
  14. Active use of tetrahydrocannabinol (THC) containing agents within four weeks prior to enrollment or during the trial. Use of cannabidiol- (CBD) / cannabimovone- (CBM) containing agents without THC is allowed if started more than eight weeks before enrollment in a stable dose/frequency.
  15. Use of antibiotics or antiviral drugs at therapeutic dose within one week before randomization. Use of antibiotics at a prophylactic dose is allowed if started at least four weeks before randomization (Section 4.2).
  16. Severe liver disease (alanine aminotransferase [ALT] three times above normal value).
  17. Known hepatitis B, hepatitis C or HIV infection as per patient medical history.
  18. Cardiac insufficiency (New York Heart Association [NYHA] classification III-IV), cardiomyopathy, significant cardiac dysrhythmia requiring treatment.
  19. Medical conditions with symptoms and effects that could alter protein catabolism and/or IgG utilization (e.g. protein-losing enteropathies, nephrotic syndrome).
  20. Pregnant and/or lactating women.
  21. Female patients of childbearing potential unwilling to use a protocol-required method of contraception (as per protocol Section 7.3.9 b) from Screening throughout the study treatment period and for four weeks following the last dose of study drug. A woman of childbearing potential is defined as a fertile woman or adolescent, from the beginning of menstruation, unless permanently sterile.
  22. Participation in another interventional clinical trial that is either blinded or involves an investigational (not approved) product within three months before Baseline or during the course of the clinical study. Participation in observational clinical trials or open-label trials involving an approved product may be permitted after consultation with the medical monitor.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04508530

Layout table for location contacts
Contact: Patrick Murphy 866-337-1868 ctgov@clinicalresearchmgt.com

Layout table for location information
United States, Arizona
Octapharma Research Site Recruiting
Tucson, Arizona, United States, 85712
United States, Arkansas
Octapharma Research Site Recruiting
Little Rock, Arkansas, United States, 72202
United States, California
Octapharma Research Site Recruiting
Los Angeles, California, United States, 90024
Octapharma Research Site Recruiting
Palo Alto, California, United States, 94305
United States, Colorado
Octapharma Research Site Recruiting
Centennial, Colorado, United States, 80112
United States, Massachusetts
Octapharma Research Site Recruiting
Boston, Massachusetts, United States, 02114
United States, New Hampshire
Octapharma Research Site Recruiting
Lebanon, New Hampshire, United States, 03756
Octapharma Research Site Recruiting
Goteborg, Sweden, 41685
Octapharma Research Site Recruiting
Stockholm, Sweden, 17164
Sponsors and Collaborators
Layout table for additonal information
Responsible Party: Octapharma
ClinicalTrials.gov Identifier: NCT04508530    
Other Study ID Numbers: NGAM-13
First Posted: August 11, 2020    Key Record Dates
Last Update Posted: May 12, 2023
Last Verified: May 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pathologic Processes